NCT06655324 A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
| NCT ID | NCT06655324 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Merck Sharp & Dohme LLC |
| Condition | Healthy |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-12-05 |
| Primary Completion | 2028-07-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 250 participants in total. It began in 2024-12-05 with a primary completion date of 2028-07-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.
Eligibility Criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization. * Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17. Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment. * Has any immunosuppressive medical condition or receive any immunosuppressive therapy.
Contact & Investigator
Medical Director
STUDY DIRECTOR
Merck Sharp & Dohme LLC
Frequently Asked Questions
Who can join the NCT06655324 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 30 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06655324 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06655324 currently recruiting?
Yes, NCT06655324 is actively recruiting participants. Contact the research team at Trialsites@msd.com for enrollment information.
Where is the NCT06655324 trial being conducted?
This trial is being conducted at Glendale, United States, Miami, United States, Kansas City, United States, Springfield, United States and 5 additional locations.
Who is sponsoring the NCT06655324 clinical trial?
NCT06655324 is sponsored by Merck Sharp & Dohme LLC. The principal investigator is Medical Director at Merck Sharp & Dohme LLC. The trial plans to enroll 250 participants.